ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,685.95
0.84%
S&P 500
5,307.01
-0.27%
Dow Jones
39,671.04
-0.51%
US Dollar vs Yen
156.7685
0.04%
Brent Oil
81.735
0.25%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) ニュース

BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:BMY
日付受信時刻ニュースソース見出しコード企業名
2024/05/2219 : 59Business WireBristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income CountriesNYSE:BMYBristol Myers Squibb Co
2024/05/2216 : 30PR Newswire (US)NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers SquibbNYSE:BMYBristol Myers Squibb Co
2024/05/2216 : 30PR Newswire (US)NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers SquibbNYSE:BMYBristol Myers Squibb Co
2024/05/2121 : 45Business WireBristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible CampaignNYSE:BMYBristol Myers Squibb Co
2024/05/2119 : 59Business WireBristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
2024/05/1623 : 26Business WireNew Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque PsoriasisNYSE:BMYBristol Myers Squibb Co
2024/05/1609 : 57Business WireBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular LymphomaNYSE:BMYBristol Myers Squibb Co
2024/05/1320 : 16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNYSE:BMYBristol Myers Squibb Co
2024/05/1105 : 30Business WireBristol Myers Squibb Provides Update on Phase 3 CheckMate -73L TrialNYSE:BMYBristol Myers Squibb Co
2024/05/0719 : 59Business WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
2024/05/0619 : 59Business WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...NYSE:BMYBristol Myers Squibb Co
2024/05/0619 : 59Business WireU.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
2024/05/0121 : 00GlobeNewswire Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationNYSE:BMYBristol Myers Squibb Co
2024/04/2919 : 00PR Newswire (US)Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune DiseasesNYSE:BMYBristol Myers Squibb Co
2024/04/2619 : 59Business WireCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaNYSE:BMYBristol Myers Squibb Co
2024/04/2520 : 53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNYSE:BMYBristol Myers Squibb Co
2024/04/2519 : 59Business WireBristol Myers Squibb Reports First Quarter Financial Results for 2024NYSE:BMYBristol Myers Squibb Co
2024/04/2320 : 25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:BMYBristol Myers Squibb Co
2024/04/2219 : 59Business WireBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, FasterNYSE:BMYBristol Myers Squibb Co
2024/04/2219 : 59Business WireBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, FasterNYSE:BMYBristol Myers Squibb Co
2024/04/0900 : 30Business WireKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)NYSE:BMYBristol Myers Squibb Co
2024/04/0702 : 15Business Wire Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
2024/04/0702 : 15Business WireBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
2024/04/0522 : 05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNYSE:BMYBristol Myers Squibb Co
2024/04/0309 : 08Business WireEuropean Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)NYSE:BMYBristol Myers Squibb Co
2024/04/0219 : 59Business WireBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term GoalsNYSE:BMYBristol Myers Squibb Co
2024/03/2905 : 05Business WireBristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…NYSE:BMYBristol Myers Squibb Co
2024/03/2905 : 01Business WireBristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s DiseaseNYSE:BMYBristol Myers Squibb Co
2024/03/2820 : 30GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsNYSE:BMYBristol Myers Squibb Co
2024/03/2703 : 25Business WireA Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de SaúdeNYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

最近閲覧した銘柄

NYSE
AXP
American Express
NYSE
NKE
Nike
COIN
ETHUSD
Ethereum
SPI
SP500
S&P 500
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US100
US Tech 100
NYSE
VZ
Verizon Communications
FX
USDGBP
US Dollar vs Sterling
NASDAQ
AMZN
Amazon.com
PM
XAUUSD
Gold vs US Dollar
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有